← Leaderboards
Andrea A. Kovacs
University Of Southern California
$11,647,115
Attributed
$13,391,112
Total exposure
21
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $916.2K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$13,391,112 · 21
By mechanism
R01$10,347,769 · 2
M01$1,723,735 · 17
R56$1,319,608 · 2
Top collaborators
- Phyllis C Tien5 shared
Most similar at University Of Southern California
Same institution · by research overlap
- Magnus Nordborg$4,357,860
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationPediatric AidsHiv InfectionsCombination ChemotherapyAids TherapyDrug Screening /EvaluationChild (0-11)Vertical TransmissionInfant Human (0-1 Year)FemaleHepatitis CZidovudineImmuneInfectionPharmacokineticsSamplingChild Physical DevelopmentCytokineCd4 Positive T LymphocytesWomanHepatitis C VirusHuman Immunodeficiency Virus
Grant awards (73)
Pathogenesis and Outcomes of SARS-CoV-2 In Utero Transmission - Immunologic and Virologic Evaluations$664,837
R56 · FY2024 · AI · contact PI
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women$672,140
R01 · FY2021 · DA · contact PI
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women$684,441
R01 · FY2020 · DA · contact PI
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women$694,955
R01 · FY2019 · DA · contact PI
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women$705,013
R01 · FY2018 · DA · contact PI
Long-term Effects of IDU, HIV, HCV and the Impact of HCV Cure on Immune Activation and Liver Fibrosis in Aging Women$731,445
R01 · FY2017 · DA · contact PI
HIV AND HCV DISEASE PROGRESSION IN WOMEN ON HAART$654,771
R56 · FY2014 · AI · contact PI
HCV and HIV Progression in Women on HAART$576,980
R01 · FY2011 · AI · contact PI
HCV and HIV Progression in Women on HAART$582,407
R01 · FY2010 · AI · contact PI
HCV and HIV Progression in Women on HAART$292,287
R01 · FY2010 · AI · contact PI
HCV and HIV Progression in Women on HAART$651,390
R01 · FY2009 · AI · contact PI
HCV and HIV Progression in Women on HAART$74,130
R01 · FY2009 · AI · contact PI
HCV and HIV Progression in Women on HAART$533,057
R01 · FY2008 · AI · contact PI
AN OPEN-LABEL STUDY OF A ONCE DAILY DOSE OF EMTRICITABINE IN COMBINATION WITH$3,025
M01 · FY2006 · RR · contact PI
HCV and Progression of HIV and HAART Response in Women$905,437
R01 · FY2005 · AI
AN OPEN-LABEL STUDY OF A ONCE DAILY DOSE OF EMTRICITABINE IN COMBINATION WITH$4,305
M01 · FY2005 · RR
PREVALENCE OF MORPHOLOGIC AND METABOLIC ABNORMALITIES IN HIV INFECTED$4,305
M01 · FY2005 · RR
ACTG 265: A PHASE I/II STUDY OF SAFETY &IMMUNOGENICITY OF LIVE-ATTENUATED$2,149
M01 · FY2005 · RR
HCV and Progression of HIV and HAART Response in Women$1,036,623
R01 · FY2004 · AI
OPEN-LABEL STUDY OF A ONCE DAILY DOSE OF EMTRICITABINE$17,201
M01 · FY2004 · RR
ACTG 265: A PHASE I/II STUDY OF SAFETY &IMMUNOGENICITY OF LIVE-ATTENUATED$6,450
M01 · FY2004 · RR
HCV and Progression of HIV and HAART Response in Women$1,155,400
R01 · FY2003 · AI
HCV and Progression of HIV and HAART Response in Women$1,052,064
R01 · FY2002 · AI
INCREASED CALORIC DENSITY INFANT FORMULA ON GROWTH &NUTRITION$0
M01 · FY2002 · RR
1592U89 W/ STANDARD ZVD THERAPY IN NEONATES BORN TO HIV WOMEN$0
M01 · FY2002 · RR
PHASE II SEROCONVERSION OF SINGLE DOSE AND TWO DOSE MEASLES VACCINATION$0
M01 · FY2002 · RR
MICRONIZED ATOVAQUONE AND AZITHROMYCIN (AT/AZ) AS COMPARED TO (TMP/SMX)$0
M01 · FY2002 · RR
PEDIATRIC LATE OUTCOME PROTOCOL$0
M01 · FY2002 · RR
HUMAN CYTOMEGALOVIRUS, MONOKINES, AND MATERNAL TRANSMISSION OF HIV$0
M01 · FY2002 · RR
ROLLING ARM MASTER PROTOCOL (PRAM) OF NOVEL ANTIRETROVIRAL$0
M01 · FY2002 · RR
PEDIATRIC/MATERNAL HIV ASSOCIATED DEMENTIA AND ROLE OF HERPES VIRUS$0
M01 · FY2002 · RR
ROLLING ARM MASTER PROTOCOL (PRAM) OF NOVEL ANTIRETROVIRAL$155,764
M01 · FY2001 · RR
PEDIATRIC/MATERNAL HIV ASSOCIATED DEMENTIA AND ROLE OF HERPES VIRUS$155,764
M01 · FY2001 · RR
HUMAN CYTOMEGALOVIRUS, MONOKINES, AND MATERNAL TRANSMISSION OF HIV$155,764
M01 · FY2001 · RR
PEDIATRIC LATE OUTCOME PROTOCOL$155,764
M01 · FY2001 · RR
MICRONIZED ATOVAQUONE AND AZITHROMYCIN (AT/AZ) AS COMPARED TO (TMP/SMX)$155,764
M01 · FY2001 · RR
PHASE II SEROCONVERSION OF SINGLE DOSE AND TWO DOSE MEASLES VACCINATION$155,764
M01 · FY2001 · RR
INCREASED CALORIC DENSITY INFANT FORMULA ON GROWTH &NUTRITION$155,764
M01 · FY2001 · RR
1592U89 W/ STANDARD ZVD THERAPY IN NEONATES BORN TO HIV WOMEN$155,764
M01 · FY2001 · RR
INCREASED CALORIC DENSITY INFANT FORMULA ON GROWTH &NUTRITION$0
M01 · FY2001 · RR
PEDIATRIC/MATERNAL HIV ASSOCIATED DEMENTIA AND ROLE OF HERPES VIRUS$0
M01 · FY2001 · RR
HUMAN CYTOMEGALOVIRUS, MONOKINES, AND MATERNAL TRANSMISSION OF HIV$0
M01 · FY2001 · RR
PEDIATRIC LATE OUTCOME PROTOCOL$0
M01 · FY2001 · RR
MICRONIZED ATOVAQUONE AND AZITHROMYCIN (AT/AZ) AS COMPARED TO (TMP/SMX)$0
M01 · FY2001 · RR
PHASE II SEROCONVERSION OF SINGLE DOSE AND TWO DOSE MEASLES VACCINATION$0
M01 · FY2001 · RR
1592U89 W/ STANDARD ZVD THERAPY IN NEONATES BORN TO HIV WOMEN$0
M01 · FY2001 · RR
ROLLING ARM MASTER PROTOCOL (PRAM) OF NOVEL ANTIRETROVIRAL$0
M01 · FY2001 · RR
1592U89 W/ STANDARD ZVD THERAPY IN NEONATES BORN TO HIV WOMEN$155,764
M01 · FY2000 · RR
PEDIATRIC/MATERNAL HIV ASSOCIATED DEMENTIA AND ROLE OF HERPES VIRUS$35,553
M01 · FY2000 · RR
ROLLING ARM MASTER PROTOCOL (PRAM) OF NOVEL ANTIRETROVIRAL$35,553
M01 · FY2000 · RR
1592U89 W/ STANDARD ZVD THERAPY IN NEONATES BORN TO HIV WOMEN$35,553
M01 · FY2000 · RR
INCREASED CALORIC DENSITY INFANT FORMULA ON GROWTH &NUTRITION$35,553
M01 · FY2000 · RR
PHASE II SEROCONVERSION OF SINGLE DOSE AND TWO DOSE MEASLES VACCINATION$35,553
M01 · FY2000 · RR
MICRONIZED ATOVAQUONE AND AZITHROMYCIN (AT/AZ) AS COMPARED TO (TMP/SMX)$35,553
M01 · FY2000 · RR
PEDIATRIC LATE OUTCOME PROTOCOL$35,553
M01 · FY2000 · RR
HUMAN CYTOMEGALOVIRUS, MONOKINES, AND MATERNAL TRANSMISSION OF HIV$35,553
M01 · FY2000 · RR
ZIDOVUDINE IN PREMATURE INFANTS EXPOSED TO HIV$0
M01 · FY2000 · RR
ZIDOVUDINE IN PREMATURE INFANTS EXPOSED TO HIV$0
M01 · FY2000 · RR
ROLLING ARM MASTER PROTOCOL (PRAM) OF NOVEL ANTIRETROVIRAL$0
M01 · FY2000 · RR
PEDIATRIC/MATERNAL HIV ASSOCIATED DEMENTIA AND ROLE OF HERPES VIRUS$0
M01 · FY2000 · RR
MICRONIZED ATOVAQUONE AND AZITHROMYCIN (AT/AZ) AS COMPARED TO (TMP/SMX)$0
M01 · FY2000 · RR
INTRON A /RIBAVIRIN IN PEDIATRIC PTS W CHRONIC HEPATITIS$0
M01 · FY2000 · RR
HUMAN CYTOMEGALOVIRUS, MONOKINES, AND MATERNAL TRANSMISSION OF HIV$0
M01 · FY2000 · RR
INCREASED CALORIC DENSITY INFANT FORMULA ON GROWTH &NUTRITION$0
M01 · FY2000 · RR
PHASE II SEROCONVERSION OF SINGLE DOSE AND TWO DOSE MEASLES VACCINATION$0
M01 · FY2000 · RR
PEDIATRIC LATE OUTCOME PROTOCOL$0
M01 · FY2000 · RR
INTRON A /RIBAVIRIN IN PEDIATRIC PTS W CHRONIC HEPATITIS$0
M01 · FY2000 · RR
ACTG 382: DMP 266 (EFAVIRENZ) AND NELFINAVIR IN CHILDREN$0
M01 · FY2000 · RR
ACTG 382: DMP 266 (EFAVIRENZ) AND NELFINAVIR IN CHILDREN$0
M01 · FY2000 · RR
ACTG 377: 4 ANTIRETROVIRAL REGIMENS W PROTEASE INHIBITORS, NRTIS AND NNRTI$0
M01 · FY2000 · RR
ACTG 377: 4 ANTIRETROVIRAL REGIMENS W PROTEASE INHIBITORS, NRTIS AND NNRTI$0
M01 · FY2000 · RR
ACTG 366: RAD-1 ANTIRETROVIRAL MANAGEMENT ALGORITHM$0
M01 · FY2000 · RR
ACTG 366: RAD-1 ANTIRETROVIRAL MANAGEMENT ALGORITHM$0
M01 · FY2000 · RR